Wu J
Department of Medical Microbiology, School of Basic Medical Sciences, Shanghai Institute of Liver Diseases; Department of Gastroenterology & Hepatology, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai 200032, China.
Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):415-419. doi: 10.3760/cma.j.issn.1007-3418.2019.06.005.
Main indication of nonalcoholic steatohepatitis (NASH) progression is hepatic fibrosis. The extent of fibrosis correlates negatively with long-term comorbidity and survival of NASH patients. Clinical screening for hepatic fibrosis extent higher than F2 is a main criterion for high risk NASH patients. Currently on-going phase III clinical trials for potential pharmacotherapeutics recruit NASH patients with F2-3, and whether tested pharmacotherapeutics block hepatic fibrosis is one of main end-points for assessment of clinical efficacy. Therefore, understanding molecular mechanisms and identifying potential targets are critical for intervention of NASH progression.
非酒精性脂肪性肝炎（NASH）进展的主要指征是肝纤维化。纤维化程度与NASH患者的长期合并症及生存率呈负相关。临床筛查肝纤维化程度高于F2是高危NASH患者的主要标准。目前正在进行的潜在药物治疗的III期临床试验招募F2 - 3期的NASH患者，所测试的药物是否能阻止肝纤维化是评估临床疗效的主要终点之一。因此，了解分子机制并确定潜在靶点对于干预NASH进展至关重要。
